glp-1 and dry mouth Managing While on Medications GLP-1 Receptor Agonists in Periodontology:

This extreme width tells us the estimate is imprecise

In Phase 1 studies, survodutide was generally well tolerated, with no significant safety or tolerability issues observed in either healthy individuals with overweight or obesity [87, 88]

The third consideration is risk management and longterm outcomes

However, several indirect mechanisms may explain why some individuals experience breathing changes whilst taking this medication

Poster Jain MR, Giri SR, Trivedi C et al (2015) Saroglitazar, a novel PPARalpha/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models